HIV Therapy Without Integrase Inhibitor: Practical Advantages and Targeted Patient Populations

EP: 1.HIV Viral Suppression: Clinical Significance and Impact on Patient Outcomes

EP: 2.Changing Patient Demographics in HIV and Impacts of Polypharmacy on Treatment

EP: 3.Phase 3 HIV Treatment Switch Studies: Key Findings From Recent Clinical Trials

Now Viewing

EP: 4.HIV Therapy Without Integrase Inhibitor: Practical Advantages and Targeted Patient Populations

EP: 5.Long-Acting HIV Therapies: Real-World Data and Clinical Application

EP: 6.CD4 T-cell and Lymphocyte Monitoring: Clinical Significance in HIV Treatment

EP: 7.CROI 2025 Insights: Evolving HIV Treatment Landscape and Practice-Changing Developments

Switch Study From Any Prior Antiretroviral Therapy

Key Themes:

• Broader Switch Strategy: A second companion study examined switching from any stable antiretroviral regimen to doravirine/islatravir.
• Noninferiority Results: The new combination demonstrated similar efficacy to continuing prior therapy with 90% to 95% virologic suppression.
• Resistance Analysis: Few cases of treatment failure were attributed to preexisting resistance mutations.
• Practical Considerations: Positioning of this nonnucleoside reverse transcriptase inhibitor–based combination in current treatment paradigms dominated by integrase inhibitors

Notable Insights From Dr Sharon Walmsley:

• Several virologic failures were detected, but analysis revealed these were due to preexisting mutations in patients who should not have been enrolled.
• The new combination offers an alternative to integrase inhibitor-based regimens, which currently dominate treatment guidelines.
• Clinicians will need to determine appropriate patient selection criteria, with potential advantages for those with integrase inhibitor resistance or intolerance.
• More adverse events were reported when switching to the new combination vs staying on established therapy, which is expected with any regimen change.